Phaseline

Targets › EGFR

EGFR (Epidermal growth factor receptor): drug programs, companies and trials

185 programs from 133 companies in 528 trials: 245 Phase 2, 192 Phase 1, 82 Phase 3, 9 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. (UniProt, P00533)

Open in Phaseline: the race on EGFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaOsimertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 4Non-small Cell Lung Cancer; Carcinoma; Metastatic Non-small Cell Lung Cancer; Cancer …Nov 2026
Michael HoppAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 4Non-squamous NSCLCDec 2026
Fudan UniversityBefotertinib
Third-generation selective EGFR tyrosine-kinase inhibitor
EGFRPhase 43-year Disease-free SurvivalMay 2027
Psoriasis Treatment Center of Central New JerseyDuobrii
Dual EGFR and ErbB2 inhibitor topical cream
EGFR, ERBB2Phase 4Psoriasis–
Sichuan Baili PharmaceuticalSI-B001
EGFR/HER3 bispecific antibody
EGFR, HER3Phase 3Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma …Nov 2026
Shanghai JMT-BioJMT101
Anti-EGFR monoclonal antibody
EGFRPhase 3Locally Advanced or Metastatic Non-squamous NSCLC; Local Advanced or Metastatic NSCLCNov 2026
Shanghai JMT-BioOsimertinib mesylate
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-Small Cell Lung Cancer; Local Advanced or Metastatic NSCLCNov 2026
Jiangsu Aosaikang PharmaceuticalASKC202
EGFR tyrosine kinase inhibitor
EGFRPhase 3Locally Advanced or Metastatic NSCLC; Advanced Solid TumorDec 2026
Allist PharmaceuticalsFirmonertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-small Cell Lung Carcinoma; EGFR; NSCLC; Leptomeningeal Metastasis …Dec 2026
Sun Yat-sen UniversityNimotuzumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Nasopharyngeal Carcinoma; Nasopharyngeal Carcinoma (NPC)Dec 2026
Jiangsu HengRui MedicinePyrotinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor
EGFR, ERBB2Phase 3Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer …Dec 2026
Dizal PharmaceuticalsSunvozertinib
EGFR Exon20ins inhibitor
EGFRPhase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer …Dec 2026
Johnson & Johnson (Janssen)Amivantamab
Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor
EGFR, METPhase 3Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck …Dec 2026
ArriVent BioPharmaFirmonertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Metastatic Non-Small Cell Lung Cancer; Non-Small-Cell Lung Cancer; Non-Small Cell Lung Cancer (NSCLC)Dec 2026
Jiangsu Hansoh PharmaceuticalHS-10504
EGFR C797S mutation-targeting tyrosine kinase inhibitor
EGFRPhase 3Advanced or Metastatic NSCLC; Locally Advanced or Metastatic NSCLCDec 2026
Johnson & Johnson (Janssen)Lazertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced or Metastatic Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-small-Cell Lung; Non-Small-Cell Lung Cancer …Dec 2026
Jiangsu Hansoh PharmaceuticalAumolertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Lung Cancer …Jan 2027
PfizerCetuximab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Neoplasms; Metastatic Colorectal CancerJan 2027
National Cancer Institute (NCI)Erlotinib Hydrochloride
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Hereditary Leiomyomatosis and Renal Cell Carcinoma; Adult Solid Neoplasm …Feb 2027
Betta PharmaceuticalsBefotertinib
EGFR tyrosine kinase inhibitor
EGFRPhase 3Non-Small Cell Lung Cancer; NSCLC; DDI (Drug-Drug Interaction); Non-small Cell Lung Cancer (NSCLC) …Apr 2027
Taiho OncologyCln-081 (TAS6417)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation; Lung Cancer; Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsMay 2027
Fudan UniversityNimotuzumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Nasopharyngeal Carcinoma; Head and Neck Squamous Cell CarcinomaMay 2027
Rakuten MedicalASP-1929 Photoimmunotherapy (PIT)
Anti-EGFR photoimmunotherapy agent
EGFRPhase 3Head and Neck Cancer; Recurrent Head and Neck Squamous Cell CarcinomaJun 2027
Sunshine Lake PharmaLarotinib
EGFR tyrosine kinase inhibitor
EGFRPhase 3Esophageal CancerAug 2027
GenmabPetosemtamab (MCLA-158)
bispecific antibody targeting EGFR and LGR5
EGFR, CEACAM5, LGR5Phase 3Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid TumorsJan 2028
Nanjing Sanhome PharmaceuticalSH-1028 tablets
EGFR tyrosine kinase inhibitor
EGFRPhase 3Non-small Cell Lung CancerFeb 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Early-stage Breast CancerFeb 2028
AmgenPanitumumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Metastatic Colorectal Cancer; Advanced Solid Tumors; Colorectal Cancer Stage IV; Colorectal Neoplasms …Jul 2028
Region SkaneAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
Rakuten MedicalCetuximab Sarotalocan (ASP-1929)
Epidermal growth factor receptor erbB1 binding agent
EGFRPhase 3Recurrent Head and Neck Squamous Cell CarcinomaSep 2028
Region SkaneDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
Allist PharmaceuticalsFurmonertinib Mesilate Tablets
EGFR tyrosine kinase inhibitor
EGFRPhase 3NSCLC Patients With Brain MetastasisMar 2029
Merck & Co. (MSD)Cetuximab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Colon Adenocarcinoma; Lung Neoplasm MalignantMar 2029
Taizhou Mabtech PharmaceuticalEnlituo®
EGFR inhibitor monoclonal antibody
EGFRPhase 3Colorectal Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Oct 2029
Allist PharmaceuticalsAlflutinib Mesylate (AST2818)
EGFR tyrosine kinase inhibitor
EGFRPhase 3Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer–
TakedaMobocertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung–
Avistone BiotechnologyPLB1004
EGFR inhibitor
EGFRPhase 2Non-Small-Cell Lung Cancer; NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung CancerNov 2026
Fundación GECPBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Lung CancerNov 2026
Hansoh BioMedical R&D CompanyHS-20117-2 Injection
EGFR-MET bispecific antibody
EGFR, METPhase 2Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid TumorsDec 2026
Peking University Cancer Hospital & InstituteIcotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non-Small Cell Lung CancerDec 2026
Shanghai Pulmonary Hospital, Shanghai, ChinaLimertinib
3rd generation EGFR tyrosine kinase inhibitor (TKI)
EGFRPhase 2EGFR-mutant Non-small Cell Lung CancerDec 2026
National University Hospital, SingaporeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLCDec 2026
Yale UniversityAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2HER2/Neu+ Uterine Serous CarcinomaDec 2026
University Medical Center GroningenCetuximab-800CW
EGFR inhibitor conjugated with NIR fluorophore (800CW)
EGFRPhase 2Barrett's Esophagus Without DysplasiaDec 2026
Ruth O'ReganNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerDec 2026
Hunan Province Tumor HospitalErlotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non Small Cell Lung CancerDec 2026
Hunan Province Tumor HospitalGefitinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non Small Cell Lung CancerDec 2026
Xuekui LiuBecotatug Vedotin
EGFR-directed antibody-drug conjugate with MMAE payload
EGFRPhase 2Head and Neck Squamous Cell Carcinoma, HNSCCDec 2026
National Cancer Institute (NCI)Afatinib Dimaleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced LymphomaJan 2027
Zhejiang UniversityNimotuzumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Metastatic Pancreatic Carcinoma; Borderline Resectable Pancreatic AdenocarcinomaFeb 2027
H. Lee Moffitt Cancer Center and Research InstituteAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Squamous Cell CarcinomaFeb 2027
National Cancer Institute (NCI)Neratinib Maleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid NeoplasmFeb 2027
National Cancer Centre, SingaporeDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IIIB; Advanced Solid TumoursApr 2027
City of Hope Medical CenterLapatinib ditosylate
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Breast NeoplasmsApr 2027
Hunan Province Tumor HospitalSunvozertinib
EGFR inhibitor
EGFRPhase 2Non-Small Cell Lung Cancer; Non-small Cell Lung CancerApr 2027
Shanghai Chest HospitalDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC)May 2027
BeBetter MedBEBT-109
EGFR exon 20 insertion inhibitor
EGFRPhase 2Non-Small Cell Lung Cancer; Non Small Cell Lung CancerJun 2027
Shanghai Junshi Bioscience Co., Ltd.JS212 for Injection
Bispecific antibody-drug conjugate targeting EGFR and HER3 with topoisomerase I inhibitor
EGFR, HER3Phase 2Advanced Esophageal Squamous Cell Carcinoma; Advanced Malignant Solid Tumors; Advanced Lung Cancer; Metastatic Colorectal Cancer …Jun 2027
Wayshine BiopharmWSD0922-FU
EGFR-TKI (third-generation)
EGFRPhase 2Non Small Cell Lung Cancer; EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer (NSCLC)Jun 2027
Second Affiliated Hospital, Zhejiang University, School of Medicinebefotertinib
third-generation EGFR tyrosine kinase inhibitor targeting non-classical EGFR mutations
EGFRPhase 2NSCLC (Non-small Cell Lung Cancer)Jun 2027
NovartisNazartinib
Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor
EGFRPhase 2Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung CancerJul 2027
University Health Network, TorontoNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerJul 2027
Fudan UniversityVebrekotuzumab
EGFR-targeting antibody-drug conjugate (ADC)
EGFRPhase 2Esophageal Squamous Cell CarcinomaAug 2027
Fudan UniversityEGFR-TKI
EGFR tyrosine kinase inhibitor (3rd generation)
EGFRPhase 2Brain MetastasesAug 2027
University of Texas Southwestern Medical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Squamous Non Small Cell Lung CancerSep 2027
University of RochesterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerSep 2027
National Taiwan University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IVOct 2027
Bicara TherapeuticsFicerafusp alfa (BCA101)
Bispecific antibody targeting EGFR and TGF-β
EGFR, TGFB1Phase 2Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN)Oct 2027
Massachusetts General HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Lung Cancer; Advanced Solid TumorDec 2027
Massachusetts General HospitalErlotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non-small Cell Lung CancerDec 2027
Teligene USSutetinib Maleate Capsule
EGFR tyrosine kinase inhibitor targeting uncommon mutations (L861Q, G719X, S768I)
EGFRPhase 2Non-small Cell Lung CancerDec 2027
Black Diamond Therapeuticssilevertinib (BDTX-1535)
4th generation irreversible EGFR inhibitor targeting classical and non-classical driver an
EGFRPhase 2Glioblastoma (GBM); Non-Small Cell Lung CancerDec 2027
Sun Yat-sen UniversityBefotertinib
Irreversible, third-generation, mutant-selective EGFR inhibitor
EGFRPhase 2Non-small Cell Lung Cancer MetastaticDec 2027
Sun Yat-sen UniversityIcotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non-small Cell Lung Cancer MetastaticDec 2027
Shanghai EpimAb BiotherapeuticsBafisontamab (EMB-01)
Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
MET, EGFRPhase 2Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal CancerDec 2027
Shanghai Henlius BiotechPimurutamab (HLX07)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Carcinoma of Head and/or Neck; Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Rectal CancerDec 2027
Shandong Public Health Clinical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Carcinoma, Non-Small-Cell LungDec 2027
Fujian Cancer HospitalMRG003
anti-EGFR monoclonal antibody
EGFRPhase 2Nasopharyngeal CarcinomaDec 2027
Centre Leon BerardLapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Malignant Solid NeoplasmsJan 2028
David Reardon, MDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GlioblastomaFeb 2028
University Health Network, TorontoBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Pancreatic Ductal CarcinomaFeb 2028
Memorial Sloan Kettering Cancer CenterGefitinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2OsteosarcomaMar 2028
H. Lee Moffitt Cancer Center and Research InstituteNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GastroEsophageal CancerMar 2028
Fudan UniversityBecotatug Vedotin (MRG003)
EGFR-targeted antibody-drug conjugate
EGFRPhase 2Hepato Cellular Carcinoma (HCC); Metastatic Colorectal Cancer; Thyroid Cancer; Penile CancerApr 2028
Ji DongmeiMRG003
anti-EGFR antibody-drug conjugate
EGFRPhase 2Salivary Gland CarcinomasMay 2028
Cancer Institute and Hospital, Chinese Academy of Medical SciencesCetuximab-beta
Anti-EGFR antibody; blocks EGFR-related cancer cell growth signals
EGFRPhase 2Metastatic Colorectal Cancer (CRC)Oct 2028
Intergroupe Francophone de Cancerologie ThoraciqueBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Non Small Cell Lung CancerOct 2028
Peng ZhangBefotertinib
EGFR tyrosine kinase inhibitor
EGFRPhase 2EGFRDec 2028
Shanghai Chest HospitalOsimertinib-based adaptive treatment
Third-generation EGFR tyrosine kinase inhibitor, selective for EGFR mutations
EGFRPhase 2Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)Jan 2029
Nanfang Hospital, Southern Medical UniversityEGFR-TKIs Combined with PD-1 Monoclonal Antibody
EGFR tyrosine kinase inhibitor combined with PD-1 inhibitor
EGFR, PDCD1Phase 2Lung Cancer Non-Small Cell Cancer (NSCLC)Mar 2029
Groupe Oncologie Radiotherapie Tete et CouMRG003
EGFR-targeting antibody-drug conjugate
EGFRPhase 2Locally Advanced Head and Neck Squamous Cell CarcinomaJun 2029
Fudan UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast Cancer With Brain MetastasisAug 2029
Scott R. Plotkin, MD, PhDBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Neurofibromatosis Type 2Dec 2029
Scott R. Plotkin, MD, PhDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Neurofibromatosis Type 2Dec 2029
Spanish Breast Cancer Research GroupNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Early-stage Breast CancerJan 2030
Vanderbilt-Ingram Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Anatomic Stage I Breast CancerApr 2030
Groupe Francais De Pneumo-CancerologieBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2NSCLCOct 2030
Guangdong Association of Clinical Trialsicotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2MRDOct 2030
Dartmouth-Hitchcock Medical CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Breast CancerOct 2030
Dizal PharmaceuticalsDZD9008
EGFR inhibitor
EGFRPhase 2Non-small Cell Lung Cancer–
Baylor Breast Care CenterLapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Breast Cancer–
AstraZenecaNecitumumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 2Non-Small Cell Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma–
XIANG YANQUNNituzumab
Anti-EGFR monoclonal antibody
EGFRPhase 2Nasopharyngeal Cancer–
UNICANCERSapitinib (AZD8931)
Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, ERBB3, EGFRPhase 2Metastatic Breast Cancer–
Stanford UniversityPanitumumab-IRDye800
anti-EGFR monoclonal antibody conjugated to IRDye800CW near-infrared fluorescent dye for i
EGFRPhase 1Malignant Brain Neoplasm; Lung Carcinoma; Brain TumorNov 2026
Roswell Park Cancer InstituteRecombinant Human EGF-rP64K/Montanide ISA 51 Vaccine (CIMAvax)
EGF-directed cancer vaccine
EGFRPhase 1Advanced Head and Neck Squamous Cell CarcinomaNov 2026
University of Saskatchewan89Zr-DFO-nimotuzumab
EGFR-targeting monoclonal antibody conjugated to zirconium-89 for PET imaging
EGFRPhase 1Lung CancerDec 2026
Jiangsu Aosaikang PharmaceuticalASK120067 (Limertinib)
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Solid TumorDec 2026
Jeeyun LeeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Stomach NeoplasmDec 2026
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2922 for injection
anti-EGFR/c-Met bispecific antibody
EGFR, METPhase 1Advanced Cancer; RAS/BRAF Wild Type Colorectal CancerDec 2026
Phrontline BiopharmaTJ101
EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I
EGFR, B7H3Phase 1Lung Cancer (NSCLC)Dec 2026
Acepodia BiotechACE2016
Allogeneic gamma delta T (gdT) cell therapy engineered to target EGFR-expressing tumors
EGFRPhase 1Locally Advanced Solid TumorDec 2026
AstraZenecaFPI-2053
Bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Advanced Solid TumorDec 2026
Henan Genuine BiotechGEN-725
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Solid Tumors; Non-Small Cell Lung CancerDec 2026
Shanghai Henlius BiotechHLX05
anti-EGFR monoclonal antibody
EGFRPhase 1Cancer; EGFR OverexpressionDec 2026
AstraZeneca[111In]-FPI-2107
Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM
EGFR, METPhase 1Advanced Solid TumorDec 2026
AstraZeneca[225Ac]-FPI-2068
Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target
EGFR, METPhase 1Advanced Solid TumorDec 2026
Beijing BiotechEB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
Suzhou Zelgen BiopharmaceuticalsGecacitinib
Tyrosine kinase inhibitor targeting EGFR
EGFRPhase 1Healthy; Lymphoma; Non-small Cell Lung Cancer; Cervical Cancer …Feb 2027
Chia Tai Tianqing Pharmaceutical GroupTQB6411 for Injection
EGFR/c-Met dual-targeting antibody-drug conjugate
EGFR, METPhase 1Esophageal Cancer; Advanced Lung CancerFeb 2027
Beijing BiotechEGFR/HER2 Dual-Target CAR-NK Cells
Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re
EGFR, ERBB2Phase 1Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMar 2027
Abbisko TherapeuticsABSK112
EGFR Exon20 inhibitor
EGFRPhase 1Non-Small Cell Lung CancerMar 2027
Memorial Sloan Kettering Cancer CenterEGFRt/19-28z/4-1BBL CAR T cells
CD19-targeting CAR T cell therapy with 28z costimulatory domain and 4-1BB ligand; EGFRt se
CD19, EGFRPhase 1Chronic Lymphocytic Leukemia (CLL)Mar 2027
Shanghai Henlius BiotechHLX48
EGFR/c-MET bispecific antibody-drug conjugate
EGFR, METPhase 1Advanced/Metastatic Solid TumorsMar 2027
City of Hope Medical CenterBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Locally Advanced Lung Non-Small Cell CarcinomaMar 2027
Hangzhou Zhongmei Huadong PharmaceuticalHDM2024
Antibody-drug conjugate targeting EGFR and HER3
EGFR, HER3Phase 1Advanced Solid TumorsApr 2027
Memorial Sloan Kettering Cancer Centeranti-EGFR-bispecific antibody armed activated T-cells (EGFR BATs)
anti-EGFR bispecific antibody-armed activated T-cells
EGFRPhase 1Pancreatic CancerApr 2027
National Cancer Institute (NCI)Lapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 1Metastatic Thyroid Gland CarcinomaMay 2027
West China HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1HNSCC; Esophagus CancerMay 2027
Haisco Pharmaceutical GroupHSK40118
EGFR inhibitor
EGFRPhase 1NSCLCJun 2027
Shanghai Henlius BiotechCetuximab (HLX42)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Solid Tumor and NSCLCJun 2027
ALX OncologyALX2004
anti-EGFR antibody-drug conjugate
EGFRPhase 1NSCLC (Advanced Non-small Cell Lung Cancer)Jun 2027
Betta PharmaceuticalsCFT8919
EGFR tyrosine kinase inhibitor
EGFRPhase 1Non-Small Cell Lung Cancer With EGFR MutationJun 2027
Darell BignerD2C7-IT
EGFR-targeted immunotoxin
EGFRPhase 1Glioma, Malignant; Newly Diagnosed MGMT Unmethylated Glioblastoma; Recurrent Glioblastoma IDH WildtypeJun 2027
Dizal PharmaceuticalsDZD6008
EGFR inhibitor
EGFRPhase 1Non Small Cell Lung Cancer; Nonsmall-cell Lung Cancer; Non-Small Cell Lung CancerJun 2027
Sun Yat-sen UniversityEGFR Antibody
EGFR inhibitor antibody
EGFRPhase 1Nasopharyngeal Cancinoma (NPC)Jun 2027
Fox Chase Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Gastric CancerJun 2027
YuhanYH32364
EGFR-targeting agent
EGFRPhase 1EGFR OverexpressionJun 2027
HC BiopharmaHC034S
EGFR inhibitor monoclonal antibody (cetuximab biosimilar)
EGFRPhase 1CetuximabJun 2027
Innovent Biopharmaceutical Technology (Hangzhou)IBI3028
Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate
EGFR, METPhase 1Solid TumorJun 2027
Jonsson Comprehensive Cancer CenterERAS-801
EGFR inhibitor
EGFRPhase 1GlioblastomaJul 2027
UNC Lineberger Comprehensive Cancer CenterErlotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Pancreatic AdenocarcinomaAug 2027
Dana-Farber Cancer InstituteGefitinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Non-Small Cell Lung CancerOct 2027
Memorial Sloan Kettering Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Solid TumorOct 2027
Virginia Commonwealth UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Advanced Solid TumorOct 2027
BeOne MedicinesBG-C0902
Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p
EGFR, METPhase 1Solid TumorsNov 2027
Pierre Fabre MedicamentSTX-241
Mutant-selective CNS-penetrant fourth generation EGFR tyrosine kinase inhibitor
EGFRPhase 1Non-small Cell Lung Cancer (NSCLC)Nov 2027
M.D. Anderson Cancer CenterCytokine-treated Veto Cells
CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel
IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2Phase 1Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal CancerDec 2027
University of VirginiaEGFR FPBMC
CD3 x EGFR bispecific antibody-armed fresh peripheral blood mononuclear cells
CD3, EGFRPhase 1Pancreas CancerDec 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB6411 injection
EGFR/c-Met dual-targeting antibody-drug conjugate (ADC)
EGFR, METPhase 1Advanced Malignant TumorsDec 2027
Mustafa Khasraw, MBChB, MD, FRCP, FRACPhEGFRvIII-CD3 (BRiTE)
Bispecific T cell engager with one arm binding CD3 on T cells and the opposing arm binding
EGFR, CD3EPhase 1Newly Diagnosed GlioblastomaDec 2027
Henan Genuine BiotechDositinib mesylate tablets (90-1408)
EGFR inhibitor
EGFRPhase 1Non-Small Cell Lung CancerDec 2027
Vanderbilt-Ingram Cancer CenterPanitumumab-IRDye800
EGFR-targeted monoclonal antibody conjugated to fluorescent IRDye800 dye
EGFRPhase 1Head and Neck Squamous Cell Carcinoma; HNSCC; HNSCC,Larynx, Pharynx and Oral CavityDec 2027
YuhanYH42946
Dual EGFR exon 20 insertion and HER2 inhibitor
EGFR, ERBB2Phase 1NSCLC (Non-small Cell Lung Cancer)Mar 2028
Alpha Biopharma (Jiangsu)Azd-3759
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentApr 2028
Betta PharmaceuticalsMCLA-129
bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Solid Tumor; Solid Advanced TumorApr 2028
M.D. Anderson Cancer CenterBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Advanced Lung Carcinoma; Brain MetastasisJun 2028
Jiangsu Alphamab BiopharmaceuticalsFurmonertinib Mesylate
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Non-small Cell Lung CancerJun 2028
Changchun GeneScience PharmaceuticalGenSci139
bispecific antibody drug conjugate targeting EGFR and HER2
EGFR, HER2Phase 1Advanced Solid TumorsJul 2028
Suzhou Junjing BioSciencesJS111 capsules (AP-L1898)
EGFR inhibitor
EGFRPhase 1NSCLCJul 2028
R-PharmPanitumumab (RPH-030)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Metastatic Colorectal CancerAug 2028
BayerBAY2927088 (sevabertinib)
Tyrosine kinase inhibitor targeting mutated EGFR and HER2
EGFR, HER2Phase 1Advanced Non-small Cell Lung CancerDec 2028
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Fanconi AnemiaDec 2028
Tongji UniversityHJ-004-02
EGFR tyrosine kinase inhibitor
EGFRPhase 1NSCLC (Advanced Non-small Cell Lung Cancer)Dec 2028
VoronoiVRN110755
Selective oral EGFR inhibitor targeting activating EGFR mutations and resistance mutations
EGFRPhase 1EGFR-Mutant Non-Small Cell Lung CancerJan 2029
BlossomHill TherapeuticsBH-30643
Dual EGFR/HER2 inhibitor
EGFR, HER2Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)Jan 2029
NEOK BioNEOK002
EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC)
EGFR, MUC1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsFeb 2029
A2 BiotherapeuticsA2B395
Allogeneic logic-gated CAR T cells targeting EGFR with HLA-A*02 loss as kill-switch
EGFRPhase 1Solid Tumor, AdultMar 2029
Vanderbilt-Ingram Cancer Center[18F]NOTA-ABY030
Radiolabeled anti-EGFR affibody for PET imaging
EGFRPhase 1SCC - Squamous Cell CarcinomaApr 2029
EpiBiologicsEPI-326
tissue-selective bispecific antibody targeting EGFR
EGFRPhase 1Epidermal Growth FactorJul 2029
Vir BiotechnologyVIR-5525
EGFR-targeting immunotherapy
EGFRPhase 1Solid Tumor MalignanciesAug 2029
Pierre Fabre MedicamentSTX-721/PFL-721
Exon 20 insertion-selective tyrosine kinase inhibitor
EGFR, HER2Phase 1Non-Small Cell Lung CancerDec 2029
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2922 injection
Bispecific antibody against EGFR and c-Met
EGFR, METPhase 1Advanced CancersDec 2029
Princess Maxima Center for Pediatric OncologyBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Anaplastic Large Cell Lymphoma, ALK-PositiveDec 2033
Seattle Children's Hospitalsecond generation 4-1BBζ EGFR806-EGFRt
Dual-targeting CAR-T cell therapy against EGFR and CD19 with 4-1BB costimulation
EGFR, CD19Phase 1Pediatric Solid TumorJun 2040
China Medical University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Non-small Cell Lung Cancer–
DEKA BiosciencesDK210 (EGFR)
EGFR-targeted therapy
EGFRPhase 1Cancer–
China Medical University HospitalErlotinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Non-small Cell Lung Cancer–
China Medical University HospitalGefitinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Non-small Cell Lung Cancer–
Janux TherapeuticsJANX008
EGFR-targeting therapy
EGFRPhase 1Non-Small Cell Lung Cancer–
J Ints BioJIN-A02
4th generation EGFR tyrosine kinase inhibitor
EGFRPhase 1EGFR Mutant Advanced Non-small Cell Lung Cancer–
MerusMCLA-129
bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases
EGFR, METPhase 1Non-Small Cell Lung Cancer Metastatic–
Nalo TherapeuticsNX-019
EGFR inhibitor
EGFRPhase 1EGFR Mutation-Related Tumors–
Ascentage Pharma GroupOsimertinib Mesylate (AZD9291)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1EGFR Positive Non-small Cell Lung Cancer–
Chia Tai Tianqing Pharmaceutical GroupTQB3002
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Cancer–

Conditions

Non-Small Cell Lung Cancer (40) Non-small Cell Lung Cancer (29) Non Small Cell Lung Cancer (23) Carcinoma, Non-Small-Cell Lung (22) Breast Cancer (21) NSCLC (13) Lung Cancer (12) Head and Neck Squamous Cell Carcinoma (11) Non-Small-Cell Lung Cancer (8) Advanced Solid Tumor (8) Metastatic Lung Non-Small Cell Carcinoma (7) Metastatic Colorectal Cancer (7)

Modalities

small molecule (117), mixed (41), antibody (17), protein or peptide (4), other (3)

Companies

Fudan University (6) AstraZeneca (5) National Cancer Institute (NCI) (4) Sun Yat-sen University (4) Shanghai Henlius Biotech (4) Memorial Sloan Kettering Cancer Center (4) Allist Pharmaceuticals (3) Hunan Province Tumor Hospital (3) China Medical University Hospital (3) Dizal Pharmaceuticals (3) Vanderbilt-Ingram Cancer Center (3) Betta Pharmaceuticals (3) Jiangsu Hansoh Pharmaceutical (2) Johnson & Johnson (Janssen) (2) Massachusetts General Hospital (2) Shanghai Chest Hospital (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) H. Lee Moffitt Cancer Center and Research Institute (2) University Health Network, Toronto (2) Shanghai JMT-Bio (2)

Related targets

ERBB2 (42) ERBB4 (32) MET (15) ALK (8) HER2 (4) HER3 (3) CD19 (2) ERBB3 (1) CEACAM5 (1) LGR5 (1) B7H3 (1) MUC1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.